Advertisement

Topics

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

2018-05-22 18:49:10 | BioPortfolio

Published on BioPortfolio: 2018-05-22T18:49:10-0400

Clinical Trials [915 Associated Clinical Trials listed on BioPortfolio]

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCET...

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent che...

A Phase 1 Study of Brentuximab Vedotin Combined With ABVD for Hodgkin Lymphoma

The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with ABVD in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, single-...

Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma

The goal of this clinical research study is to compare the effectiveness of receiving Adriamycin (doxorubicin hydrochloride), bleomycin, vinblastine, and dacarbazine (ABVD) therapy alone t...

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignmen...

PubMed Articles [1410 Associated PubMed Articles listed on BioPortfolio]

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (AB...

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events.

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-expressing cells.

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

Purpose To improve the curability of older patients with newly diagnosed Hodgkin lymphoma. Patients and Methods We conducted a multicenter phase II study that administered brentuximab vedotin (Bv) seq...

Dramatic response to brentuximab vedotin in a refractory non-transformed CD30-negative mycosis fungoides allowing allogeneic stem cells transplantation and long-term complete remission.

The erythrodermic ulcerated form of mycosis fungoides (MF) is exceptional, and treatment of refractory cases is therefore very challenging. Brentuximab Vedotin (BV) is a monoclonal antibody combined w...

Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.

Medical and Biotech [MESH] Definitions

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).

A serine protease that cleaves multiple COMPLEMENT 5 into COMPLEMENT 5A (anaphylatoxin) and COMPLEMENT 5B in the CLASSICAL COMPLEMENT ACTIVATION PATHWAY. It is a complex of CLASSICAL PATHWAY C3 CONVERTASE (C4b2a) with an additional COMPLEMENT C3B, or C4b2a3b.

More From BioPortfolio on "OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial